Thank you for the submission of your manuscript to The EMBO Journal and please accept my apologies for the delay in responding due to the holiday season. I have now received the set of comments, which are copied below, from the two referees that were asked to evaluate your study. I am afraid to say that the evaluation of your manuscript is not a positive one.
As you will see from the enclosed reports, the referees do not support the publication of your work. In brief, to avoid repeating here the arguments presented below, although they find the topic interesting, they essentially conclude that your experimental evidence is not supportive of your main claims.
Considering the nature of these concerns and the fact that The EMBO Journal can only invite revision of papers that receive strong support from a majority of referees, I am afraid that we do not feel it would be productive to call for a revised version of your manuscript at this stage and therefore we cannot offer to publish it.
I am sorry that I have to disappoint you this time. I hope, however, that the referee comments will be helpful in your continued work in this area and I thank you once more for the opportunity to consider your manuscript.
• In the absence of Rab14, Nischarin can still associate to vesicles. Authors conclude that this is due to PI(3)P binding. However, there is a lack of direct evidence for this, and so sensitivity to PI(3)P levels in the absence of Rab binding should be tested to confirm that another mechanism is not responsible for recruitment via the PX domain.
• The majority of the work is based on overexpression, however Fig 1E shows that antibodies exist and work for both Nischarin and Rab14. o Does endogenous Nischarin display the same colocalisation pattern as overexpressed Nischarin? For example, with endogenous CD63 or Lamp1, Rab9, Rab14 and Rac1? Does it fail to localize to Cathepsin D positive vesicles? Quantification under these conditions will strengthen this manuscript. o Experiment in Fig 3F should also be done using endogenous protein (using Rab9 siRNA) to check that endogenous Rab9 alters Rab14/Nischarin co-localisation.
• There is general sloppy annotation of several figures leaving the reader guessing. o Total lack of time points in the manuscript in relation to the Salmonella micrographs and the Salmonella growth data (Fig 6) . This must be rectified.
• Several figures lack controls, especially for the binding assays and IPs. For example: o Fig 2B. Coomasie gels of GST-Rab14 loaded with GDP or GMP-PNP should be shown to show that equal amounts of protein were loaded to the beads to be sure that the GMP-PNP specificity is real. Further, a GST alone control should be used to determine if the binding observed for GDP is real or due to non-specific binding to GST beads. o Fig 3. C lacks all forms of controls, loading, expression levels, input levels. o Fig S2. Full blot should be shown so that GFP plasmid alone can be observed. It would be nice to see both lysate and IP blotted for both GFP and Myc. o Fig S8. In A, it is not clear where the siRNA control lies in the sPCR. In B, there is no reference for protein levels (loading controls) on the western blots.
• Whilst Nischarin dimer formation and colocalisation of Rac1, Nischarin and Rab14 to the same puncta suggest simultaneous binding could occur, they do not present enough evidence that Nischarin is a bridging molecule. Localisation of Rac1 and Rab14 to the same puncta should be analysed in Nischarin depleted cells. Further, attempts should be made to detect a Rac/Rab14 bridged complex through Nischarin.
• The authors propose that Nischarin is recruited to the SCV initially along with Rab14 and Rac1. Rac1 is then supplanted by Rab9 promoting fusion between Rab9 positive vesicles and the SCV and thereby preventing fusion with lysosomes. According to the proposed model Rab9, Rab14 and Nischarin would be expected to persist on the SCV membrane. Bakowski et al. (2010) have shown that 2 hours after internalisation there are negligible levels of Rab14 on the SCV. These data do not reconcile with the recruitment model proposed here. o Nischarin colocalisation to the SCVs should be quantified (number of positive SCVs) over several hours of infection to determine how widespread Nischarin localization is and over what time course it can have an effect. o Kinetics profiles of Nischarin recruitment to the SCV should be compared to vacuoles containing inert particles or dead bacteria to determine that Nischarin recruitment to he SCV is a deviation from the normal phagolysosomal maturation pathway preventing lysosomal fusion with the SCV.
• Thp1 cells are not appropriate to study proliferation of S. Typhimurium. This serovar is known to be adapted for survival and growth in mouse macrophage-like cells, but does not grow to any extent in human monocytes/macrophages.
Minor points:
• Typhimurium should not be in italics.
• The claim on page 3 "The recruitment of Nischarin to the SCV via PI(3)P" is too strong a claim for the evidence presented which suggests it is recruited via its N-terminal PI3P binding PX domain, but not formally shown to depend on PI(3)P.
• The claim that "Nischarin localised to endosomes despite overexpression of GDP-Rab14-N121I" on page 4 is not backed up with any co-stains for the precise localization of Nischarin in cells, for example with EEA1 or LAMP1.
• Quantification for the extent of loss of colocalisation of Rab14-Nischarin upon deletion of the CTD should be shown as colocalisation is still visible in image 2C.
• All microscopy images should be shown in black and white for each channel, followed by an overlay so that images can be assessed properly.
• Please show the data labeled as "not shown".
Referee #2
The manuscript entitled "Rac and Rab GTPases Dual Effector Nischarin Facilitates Survival of Intracellular Bacteria" by Kuijl et al., describes a new effector of Rab4, Rab14, Rac1 and Rab9, Nischarin, that is involved in endocytic trafficking and Salmonella survival. While the biochemistry evidence is strong, it is surprising that only 1 figure in 6 investigates the role of these proteins in Salmonella infection. Therefore, if the authors want to put the emphasis in Salmonella they have to substantiate much better their claims regarding the effects in Salmonella infection.
Major points: a)The use of FRAP to infer the "kinetics of release of Rab from target membranes" is questionable since it is indirect. FRAP reflects recruitment of a protein to an organelle and only indirectly can reflect the cycle of GTP hydrolysis. One would have to assume the existence of saturating conditions, i.e. only after the inactivation of a small GTPase on a membrane, and consequent extraction from that membrane, can new proteins be recruited. Direct methods such as GTP binding assays that measure the GTP/GDP bound pool of proteins or even a simple subcellular fractionation to show that more protein is membrane-bound in a certain condition should be used if the authors want to take this conclusion. b)In page 4 it is referred that "Nischarin localized to endosomes"... This is not shown with standard markers such as EEA-1, Rab5, etc. c)In the bottom of page 5, the authors conclude that Nischarin bridges Rac and Rab14 and the same could be true also for Rab9 and Rab14. To show this directly the authors should perform coimmunoprecipitations with Nischarin and detect the different small GTPases in the same immunoprecipitates. d)In Fig. 6 the authors only show one time-point for the infection (which is not clearly stated). In this case a time-course must be performed. Also the use of several different cell types makes the interpretation of this figure very confusing. The choice of cell types has to be well justified since they are not commonly found in Salmonella infection studies. e)The authors do not address what would be the cause of decreased bacterial proliferation/survival in the absence of Nischarin and the small GTPases. According to their model it could be caused by an increase in phagosome-lysosome fusion. This hypothesis should be tested, for example by monitoring the recruitment of lysosomal markers to phagosomes. f)The title is not entirely supported by the conclusions since the authors report that the overexpression of Nischarin only increases 10% the survival of Salmonella. These results should be shown. More importantly, if this is the data, then the title has to refer that the silencing of Nischarin leads to a decrease in bacterial proliferation/survival and not the opposite, which is not entirely supported by the data not shown.
Minor (but important) points: a)The correct writing for the bacterial species is Salmonella enterica (italic) serovar Typhimurium (non-italic). b)There are no molecular weight markers on any SDS-PAGE. c)Page 8 ("... but escape the fusion with lysosomal proteases")-Phagosomes fuse with lysosomes that contain proteases is the correct description. d)"Bacterial survival" and "bacterial proliferation" are used interchangeably by the authors and they are not the same. Authors should decide by one of them and justify the choice. e) Fig. 1C and D -the separate channels in black and white should be shown to give the readers the possibility of judging better the data. f) Fig. S1 is not convincing as is. Quantification of the intensity of the relevant bands could help. g) Fig. 3F could be interpreted as Rab9 and Rab14 competing for Nischarin. However, this is not reflected in the schematic of Thank you for completing the review of our manuscript in a month time despite having holiday schedule. We are pleased to see both reviewers find our manuscript interesting even though they raised many technical or editorial questions. However, we find it surprising about your final decision on not to give an opportunity to revise our manuscript.
Most of 1st reviewer major comments can be categorized into minor or editorial in nature (e.g. missing references, figure annotation, adding controls to figures, localization with organelle markers and quantification etc.). Similarly, 2nd reviewer also had few major cooments to improve the manuscript; e.g. Nischarin localization with endosomal markers (already characterized and was shown in the literature), adding additional time points for salmonella infection, revising title etc. We are confident of taking care of most of the reviewers' suggestions (above described comments and others) in the revised manuscript.
In fact, I just received acceptance of another paper from our group in a high impact journal from Nature Publishing Group (Nature Biotech), where reviewer comments (four reviewers) were lengthy and had asked for major revision (compared to this manuscript). We have successfully submitted the revised manuscript and the manuscript is in the press. Similarly, we also published another Nature Biotech few years ago and few EMBOJ papers (I was a middle author in these EMBOJ papers).
When I compare reviewers comments from the current paper to that of previous ones, these comments sound much more positive and suggested experiments are doable.
So far, journals from Nature Publishing Group always found research done and communicated from our group(s) was exciting. I hope you will reconsider your decision and give us an opportunity to revise our manuscript. Please let me know if you need any additional clarifications.
I look forward to hearing from you.
Additional Correspondence 16 January 2012
Thank you for your e-mail requesting the re-consideration of our decision on your manuscript, which I have discussed again within our editorial team taking into consideration the comments from the reviewers.
First of all, I would like to apologize for not being able to express the reasons for the rejection of your manuscript clearly enough. As I mentioned in my decision letter, both referees expressed their doubts on the conclusiveness of your experimental data and, under this circumstances, we believe that rejection was the sensible decision to make. Particularly, referee #1 explicitly remarks that the evidence presented does not support several important conclusions and referee #2 considers that the physiological effects of Nischarin on Salmonella infection are not properly analyzed. Taking these arguments into consideration, I am afraid that I do not see myself in the position of reverting our original decision.
That being said, if you can provide experimental evidence addressing all the concerns of the referees -as your rebuttal letter suggests -I would be happy to reconsider a new manuscript in the near future. To be completely clear, however, I would like to stress that a new manuscript will be treated as a new submission rather than a revision and, although reviewed by the same referees, it will be re-evaluated in terms of novelty with respect to the published literature at the time of submission.
I hope that this letter has clarified the rationale behind our decision and re-emphasized the strong demands that we have to apply according to the aim and scope of our highly competitive journal.
Resubmission -authors' response 21 November 2012
Referee #1
This manuscript identifies Nischarin as a Rac/Rab effector protein. In addition, the authors show that Nischarin is recruited to the Salmonella-containing vacuole (SCV). There is tantalizing evidence that Nischarin retains Rab GTPases on vesicles and vacuoles and could prevent these compartments from merging with lysosomes but there are several important conclusions that are not fully supported by the experimental data. For example, authors show that Nischarin knockdown decreases Salmonella replication, presumably due to an increased fusion with lysosomes / hydrolytic enzyme -positive compartments. However, the critical experiment to test the model has not been performed (i.e. scoring for hydrolytic enzyme -positive SCVs).
Response from authors: We thank the referee for thoughtful comments, which guided us conducting additional experiments. We have now included the new data in the current manuscript and modified the working model that depicts the functional role of Rab14/Rab9 and Rac GTPases and Nischarin in the intracellular survival of Salmonella.
Comment (1): There is significant lack of reference to key papers in the field. For example Drecktrah (2007) should be referenced during the introduction on SCV fusion to lysosomes as this is misleading to readers unfamiliar with the field (Fusion of SCVs to late endosomes and lysosomes has been observed using live imaging techniques).
Response from authors: We have now added several key references in the introduction and discussion sections of the manuscript.
Comment (2): Authors claim; that "The presence of Nischarin on endocytic vesicles results in the retention of small GTPases -initially Rab4/Rab14 and later Rab9 -which prevents the merger of these vesicles with lysosomes". If this is true, fusion of SCVs and lysosomes should be shown in the absence of Nischarin. This is a critical experiment to test the proposed model.
Response from authors: We appreciate the referee's careful observations and suggestions on SCV fusion with lysosomes. It is important to note that the intracellular survival of Salmonella can be modulated by two primary events: 1. Acidification of SCV, which enhances Salmonella replication; 2. Preventing fusion of SCVs with lysosomes. We agree with referee that we did not have any experimental evidence in the previous version of the manuscript on SCV fusion with lysosomes and it was simply hypothesized. We did conduct this experiment and found that in the presence or absence of Nischarin, we did not detect any changes to the status of SCV fusion with lysosomes (data not shown). Therefore, this prompted us to speculate that Nischarin may be functioning in the steps preceding to fusion with lysosme such as acidification of SCVs that is required for intracellular survival of Salmonella. We have conducted these experiments and showed that this is indeed true and we have now described this data in the Figure 6F -H. We therefore conclude that Nischarin plays a role in the endosome maturation and subsequent acidification of SCVs and the proposed model represents current findings and is also in agreement with the existing literature.
Comment (3) Fig. S3A-B) . Fig 3F (4C in the current manuscript) should also be done using endogenous protein (using Rab9 siRNA) to check that endogenous Rab9 alters Rab14/Nischarin colocalization.
Comment (4b): Experiment in
Response from Authors: Unfortunately, this experiment can not be done due to technical reasons as it involves combination of knock down (Rab9) and overexpression constructs (Rab14 and Nischarin) in A172 cells. In addition, knock-down of Rab9 also decreases the endogenous Nischarin levels ( Supplementary Fig. S5B ), which would further complicate the analysis. (Fig. 1B, Fig. 2B and Supplementary Fig.  S2A ). We have also added panel of Ponceau-S staining of western bots (Fig. 1B, Fig. 2B and Supplementary Fig. S2A ) and staining with Rab GTPase or Nischarin in the IP experiments (Fig.  1C) to describe equal loading of corresponding GTPases or Nischarin used in IP experiment.
Comment (6b): Fig 3.C lacks all forms of controls, loading, expression levels, input levels.
Response from authors: Unfortunately, we could not locate Ponceau-S staining blot for Rab4 and Rab9 GTPase interaction ( Fig. 3C) with Nischarin. However, we have added additional data describing N-terminal domain of Nischarin that does not bind to Rab4 and Rab9 ( Supplementary  Fig. S2A ) and yeast two hybrid data shows that binding is through the C-terminal domain of Nischarin ( Supplementary Fig. S3D ). Taken these data into consideration both Rab4 and Rab9 bind to the C terminal domain of Nischarin in a GTP-bound fashion, a similar pattern that seen with Rab14.
Fig S2. Full blot should be shown so that GFP plasmid alone can be observed. It would be nice to see both lysate and IP blotted for both GFP and Myc.
We have now added full size western blots of Supplementary Fig. S2C as suggested by this referee.
Fig S8. In A, it is not clear where the siRNA control lies in the sPCR. In B, there is no reference for protein levels (loading controls) on the western blots.
Response from authors: The legend of Supplementary Fig. 6C (former Fig. S8 ) describing qPCR data is now corrected. Percent of Nischarin knock-down levels are normalized to siCTRL cells, where Nischarin transcript levels are considered as 100%. Full-size western blots are shown to depict Rab9 and Rab14 knock-down levels and non-specific protein bands seen in the gel could be considered for loading controls.
Comment (7): Whilst Nischarin dimer formation and co-localisation of Rac1, Nischarin and Rab14 to the same puncta suggest simultaneous binding could occur, they do not present enough evidence that Nischarin is a bridging molecule. Localisation of Rac1 and Rab14 to the same puncta should be analysed in Nischarin depleted cells. Further, attempts should be made to detect a Rac/Rab14 bridged complex through Nischarin.
Response from authors: We could not perform Rac1 and Rab14 co-localization experiments in the Nischarin knock down A172 cells due to complexity associated with the use of combination of overexpression and siRNA knock down experiments. We have conducted biochemical experiments to isolate Rab14-Nischarin-Rab9 or Rac1-Nischarin-Rab14 hetero-trimeric complex either by immuno-precipitation , GST-Rab GTPase bead binding assay or by yeast three hybrid. We have failed to isolate this complex may be due to technical reasons. Please note these GTPases compete with each other for binding to Nischarin C-terminal binding domain in a GTP-dependent fashion. Therefore, this may complicate in conducting an appropriate biochemical experiment with similar conditions that may favor this complex formation in vivo. It is also possible that this is a transient complex or these GTPases may reside on a same vesicle where Nischarin plays as a bridging/scaffold effector protein for transient period in conducting events that require conversion of early to late endosomes. We have now modified the proposed model in the Figure 7 by incorporating these assumptions. Fig. S6B ). The proposed model now depicts both current results as well as published data on Rab recruitment to the SCV.
Comment (8): The authors propose that Nischarin is recruited to the SCV initially along with

Comment (9): Nischarin colocalisation to the SCVs should be quantified (number of positive SCVs) over several hours of infection to determine how widespread Nischarin localization is and over what time course it can have an effect.
Response from authors: These experiments have been done with endogenous Nischarin and included in the manuscript (Fig. 6D and Supplementary Fig. S6A ).
Comment (9): Kinetics profiles of Nischarin recruitment to the SCV should be compared to vacuoles containing inert particles or dead bacteria to determine that Nischarin recruitment to he SCV is a deviation from the normal phagolysosomal maturation pathway preventing lysosomal fusion with the SCV.
Response from authors: Nischarin is recruited transiently (15-40 min after endocytosis of microspheres) to endocytosed vesicles of microspheres (inert material). On the other hand, Nischarin is recruited up to 5 h and then stably associated with the phagosome (Supplementary Fig.  S6A ) indicating a deviation between inert material and bacteria. It is important to note that Salmonella secretes SopB effector which is known to regulate the PI(3)P production (Hernandez, L.
D et al. (Science 304, 1805-1807 (2004).). Thus, increased PI(3)P production by Salmonella could enhance Nischarin association with SCVs.
Comment (10): Thp1 cells are not appropriate to study proliferation of S. Typhimurium. This serovar is known to be adapted for survival and growth in mouse macrophage-like cells, but does not grow to any extent in human monocytes/macrophages.
Response from authors: Salmonella proliferation in THP1 cells was indeed not observed. We observed faster clearance of Salmonella upon knockdown of Nischarin. To address this we performed the experiment in mouse RAW264.7 macrophages as per referee's suggestion. Since were unable to obtain any significant siRNA mediated knockdown of Nischarin in these cells we therefore generated a complete Nischarin knockout cells using Zinc finger nuclease-based method. These RAW264.7 macrophages showed identical results to that described with A172 cells.
Comment (1): Typhimurium should not be in italics.
Response from authors: Corrected
Comment (2): The claim on page 3 "The recruitment of Nischarin to the SCV via PI(3)P" is too strong a claim for the evidence presented which suggests it is recruited via its N-terminal PI3P binding PX domain, but not formally shown to depend on PI(3)P.
Response from authors: We show that membrane recruitment of Nischarin requires the PX-domain and that the PI(3)P kinase inhibitor wortmanin prevents recruitment of Nischarin to the membrane. Moreover Lim, K. 
Comment (3): The claim that "Nischarin localised to endosomes despite overexpression of GDPRab14-N121I" on page 4 is not backed up with any co-stains for the precise localization of Nischarin in cells, for example with EEA1 or LAMP1.
Response from authors: We have modified the sentence to state that Nischarin remains membrane associated (page 4, 2 nd paragraph, line 6).
Comment (4): Quantification for the extent of loss of colocalisation of Rab14-Nischarin upon deletion of the CTD should be shown as colocalisation is still visible in image 2C.
Response from authors: Quantification is done and this data is now included in the manuscript (Fig.  2C) .
Comment (5): All microscopy images should be shown in black and white for each channel, followed by an overlay so that images can be assessed properly.
Response from authors: We have included separate channels for images where no quantification has been performed. However, providing separate panels for all immune-fluorescence figures described in the manuscript would take significant space. We will be happy to provide the needed data to referees/editor with separate channels for all the over-lay images if needed.
Comment (6): Please show the data labeled as "not shown".
Response from authors: There are no more data described as "not shown" in the manuscript.
Referee #2
The Response from authors: We thank referee for his/her complements on our biochemical results and providing excellent suggestions in helping us for further improving manuscript presentation. We agree with this referee, we have described all Salmonella related results in 8-multi panel figure  (Figure 6 ). It is important to note that this paper describes both identification and functional characterization of a novel Rab/Rac dual effector, therefore we had to substantiate these findings in multiple figures. We feel the current format is more attractive for readers of EMBOJ.
Major points:
Comment (a): The use of FRAP to infer the "kinetics of release of Rab from target membranes" is questionable since it is indirect. FRAP reflects recruitment of a protein to an organelle and only indirectly can reflect the cycle of GTP hydrolysis. One would have to assume the existence of saturating conditions, i.e. only after the inactivation of a small GTPase on a membrane, and consequent extraction from that membrane, can new proteins be recruited. Direct methods such as GTP binding assays that measure the GTP/GDP bound pool of proteins or even a simple subcellular fractionation to show that more protein is membrane-bound in a certain condition should be used if the authors want to take this conclusion.
Response from authors: As suggested by this referee, we have performed a subcellular fractionation for one of Nischarin binding partner (Rab9) and observed that the presence of Nischarin increased the membrane bound fraction of Rab9. We agree with the referee that FRAP is an in-direct method of measuring the role of an effector in locking given GTPase in a GTP hydrolysis cycle. FRAP is being used in the literature (Jordens I et al., Curr Biol 11: 1680-1685) and an elegant quantitative assay to assess the function of the Rab GTPase effector. We are not using solely this method to define Nischarin as a Rab effector as we have described many other supporting biochemical methods.
Comment (b): In page 4 it is referred that "Nischarin localized to endosomes"... This is not shown with standard markers such as EEA-1, Rab5, etc.
Response from authors: We have referenced previous published literature (Lim K-P & Hong W J Biol Chem 279: 54770-54782)) on Nischarin localization to early endosomes. As suggested by the referee, we have now described co-localization of Nischarin with EEA1 and CD63 and found our results are in consistent with the published literature (Lim K-P & Hong W J Biol Chem 279: 54770-54782)), where Nischarin is partially co-localized with early endosomal marker (EEA1) and found very little or no co-localization with late endosomal marker (CD63). Response from authors: We appreciate the referee's careful observations and suggestions on SCV fusion with lysosomes. It is important to note that the intracellular survival of Salmonella can be modulated by two primary events: 1. Acidification of SCV, which enhances Salmonella replication; 2. Preventing fusion of SCVs with lysosomes. We agree with referee that we did not have any experimental evidence in the previous version of the manuscript on SCV fusion with lysosomes and it was simply hypothesized. We did conduct this experiment and found that in the presence or absence of Nischarin, we did not detect any changes to the status of SCV fusion with lysosomes (data not shown). Therefore, this prompted us to speculate that Nischarin may be functioning in the steps preceding to fusion with lysosme such as acidification of SCVs that is required for intracellular survival of Salmonella. We have conducted these experiments and showed that this is indeed true and we have now described this data in the Figure 6F -H. We therefore conclude that Nischarin plays a role in the endosome maturation and subsequent acidification of SCVs and the proposed model represents current findings and is also in agreement with the existing literature. Response from authors: We appreciate referee's suggestion and have changed the term "proliferation" with "survival" keeping in mind that survival is essential for proliferation. When we specifically talk about "proliferation" we use the word "replication" instead.
Comment (f)
Comment (e): Fig. 1C and 1D Fig. 4D and Fig. 5 as well as movies support these observations. The modified model shown in the Figure 7 is in agreement with data presented in the Figure 4C (former 3F) and Figure 4D . Thank you for the re-submission of your manuscript to The EMBO Journal. It has been sent to one of the original reviewers, who now considers that your manuscript is basically ready for publication.
Comment (h): The authors only refer to the model in which Salmonella
I am therefore writing with an 'accept in principle' decision, which means that I will be happy to accept your manuscript for publication once a few more minor details have been addressed, as follows.
Browsing through the manuscript myself I have noticed that the micrographs in figures 2F, 5A, 6A/B, S3A/B, S4A. S5A/B and S7B lack scale bars, which we require for clarity. In addition, the statistical analysis of most of your results is not properly described. As a guide, statistical analyses must be described either in the Materials and Methods section or in the legend of the figure to which they apply and will include a definition of the error bars used and the number of independent experiments performed. Keep in mind that duplicates are not considered independent experiments. If the number of independent experiments is less than three, as is the case, for instance of the experiment presented in figure S5B , use of error bars is not appropriate and one representative experiment should be provided, clearly indicating this fact. Along these lines, albeit not absolutely necessary, we recommend the use of statistical significance analysis tools to further strengthen the interpretation of the results. This analysis tools chosen must be also clearly indentified either in the figure legend or in the Materials and Methods section.
As a novel initiative in The EMBO Journal, we now encourage the publication of source data, particularly for electrophoretic gels and blots, with the aim of making primary data more accessible and transparent to the reader. Although optional at the moment, would you be willing to provide a PDF file per figure that contains the original, uncropped and unprocessed scans of all or key gels used in the figures? The PDF files should be labeled with the appropriate figure/panel number, and should have molecular weight markers; further annotation could be useful but is not essential. The files will be published online with the article as supplementary "Source Data" files. If you have any questions regarding this initiative do not hesitate to contact me.
Thank you very much for your patience and congratulations in advance on a successful publication. Once these minor changes suggested are incorporated into the manuscript, you will receive an official acceptance letter with further instructions on how to proceed with the publication process.
2nd Revision -authors' response 21 December 2012
